Positive News SentimentPositive NewsNASDAQ:AKYA Akoya Biosciences (AKYA) Stock Price, News & Analysis $2.46 +0.02 (+0.82%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.43▼$2.5050-Day Range$1.94▼$2.8152-Week Range$1.88▼$7.06Volume104,409 shsAverage Volume262,080 shsMarket Capitalization$121.49 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Akoya Biosciences alerts: Email Address Akoya Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside194.7% Upside$7.25 Price TargetShort InterestBearish13.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$30,675 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.99) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.99 out of 5 starsMedical Sector643rd out of 936 stocksAnalytical Instruments Industry20th out of 27 stocks 3.4 Analyst's Opinion Consensus RatingAkoya Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkoya Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Akoya Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.43% of the float of Akoya Biosciences has been sold short.Short Interest Ratio / Days to CoverAkoya Biosciences has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Akoya Biosciences has recently increased by 14.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkoya Biosciences does not currently pay a dividend.Dividend GrowthAkoya Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKYA. Previous Next 2.5 News and Social Media Coverage News SentimentAkoya Biosciences has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Akoya Biosciences this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Akoya Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akoya Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,675.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Akoya Biosciences is held by insiders.Percentage Held by Institutions79.42% of the stock of Akoya Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Akoya Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akoya Biosciences are expected to grow in the coming year, from ($0.99) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akoya Biosciences is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akoya Biosciences is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkoya Biosciences has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akoya Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Akoya Biosciences Stock (NASDAQ:AKYA)Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.Read More AKYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKYA Stock News HeadlinesJuly 19, 2024 | markets.businessinsider.comAkoya Biosciences: Poised for Recovery and Growth Amidst Market ChallengesJuly 15, 2024 | globenewswire.comAkoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor ConferencesJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 29, 2024 | finance.yahoo.comWe Think Some Shareholders May Hesitate To Increase Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO CompensationMay 19, 2024 | msn.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2024 Earnings Call TranscriptMay 14, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)May 14, 2024 | marketwatch.comShares of Akoya Biosciences Drop After 1Q Earnings, Revenue Outlook MissMay 14, 2024 | finance.yahoo.comAkoya Biosciences Inc (AKYA) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 13, 2024 | investorplace.comAKYA Stock Earnings: Akoya Biosciences Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | globenewswire.comAkoya Biosciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comAkoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma PatientsMay 6, 2024 | globenewswire.comAkoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, MassachusettsMay 2, 2024 | globenewswire.comAkoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical WorkflowsApril 22, 2024 | globenewswire.comAkoya to Report First Quarter 2024 Financial Results on May 13th, 2024April 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)April 5, 2024 | globenewswire.comAkoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and ScaleMarch 16, 2024 | uk.investing.comAkoya Biosciences CEO sells $37k worth of sharesSee More Headlines Receive AKYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:AKYA CUSIPN/A CIK1711933 Webwww.akoyabio.com Phone855-896-8401FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$7.25 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+194.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,320,000.00 Net Margins-72.68% Pretax Margin-72.60% Return on Equity-111.80% Return on Assets-35.13% Debt Debt-to-Equity Ratio2.33 Current Ratio3.07 Quick Ratio2.38 Sales & Book Value Annual Sales$93.57 million Price / Sales1.30 Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book2.24Miscellaneous Outstanding Shares49,386,000Free Float45,781,000Market Cap$121.49 million OptionableOptionable Beta1.34 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Brian McKelligon (Age 55)President, CEO & Director Comp: $854.99kMr. John Frederick Ek (Age 48)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $496.76kDr. Frederic G. Pla Ph.D. (Age 65)Chief Operating Officer Comp: $581.23kPriyam ShahSenior Director of Business Development & Investor Relations StrategyMs. Jennifer Kamocsay (Age 53)General Counsel Dr. Niro Ramachandran Ph.D. (Age 49)Chief Business Officer Comp: $298.18kDr. Pascal Bamford Ph.D.Senior Vice President, Research & Development and Laboratory OperationsMr. Rob C. Hart CFAJ.D., SecretaryMore ExecutivesKey CompetitorsAthira PharmaNASDAQ:ATHAPrelude TherapeuticsNASDAQ:PRLDSutro BiopharmaNASDAQ:STRONautilus BiotechnologyNASDAQ:NAUTHarvard BioscienceNASDAQ:HBIOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 9,429 shares on 7/26/2024Ownership: 0.137%Peddock Capital Advisors LLCSold 5,124 shares on 7/19/2024Ownership: 0.476%Brian MckelligonSold 7,500 sharesTotal: $15,600.00 ($2.08/share)Brian MckelligonSold 7,500 sharesTotal: $15,075.00 ($2.01/share)Silvercrest Asset Management Group LLCBought 580,834 shares on 5/16/2024Ownership: 1.176%View All Insider TransactionsView All Institutional Transactions AKYA Stock Analysis - Frequently Asked Questions How have AKYA shares performed this year? Akoya Biosciences' stock was trading at $4.88 at the start of the year. Since then, AKYA stock has decreased by 49.6% and is now trading at $2.46. View the best growth stocks for 2024 here. How were Akoya Biosciences' earnings last quarter? Akoya Biosciences, Inc. (NASDAQ:AKYA) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The firm earned $18.35 million during the quarter, compared to analyst estimates of $24.13 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 111.80% and a negative net margin of 72.68%. When did Akoya Biosciences IPO? Akoya Biosciences (AKYA) raised $125 million in an IPO on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO. Who are Akoya Biosciences' major shareholders? Top institutional shareholders of Akoya Biosciences include Peddock Capital Advisors LLC (0.48%), Bank of New York Mellon Corp (0.14%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Matthew Winkler, Garry PhD Nolan, Brian Mckelligon, Frederic Pla, John Frederick Ek, Joseph Driscoll, Niro PhD Ramachandran and Robert G Shepler. View institutional ownership trends. How do I buy shares of Akoya Biosciences? Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKYA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
